Table 2.

Analyses for the use of lipid-lowering therapies and CRP change.

Treatment	Participant	WMD (mg/L)	95% CI (mg/L)	P value	I2 (%)	Subgroups difference (P value)
Statins	18,785/17,668	−0.67	−0.90 to −0.45	<.001	97	<.001
Ezetimibe	9872/9886	−0.64	−1.07 to −0.21	.003	74
PCKS9-mAbs	15,789/15,401	−0.06	−0.17 to 0.05	.32	46

CI = confidence interval, CRP = C-reactive protein, PCSK9-mAb = proprotein convertase subtilisin/kexin type 9 monoclonal antibody, WMD = weighted mean difference.